Insider Transactions in Q3 2020 at Pandion Therapeutics, Inc. (PAND)
Insider Transaction List (Q3 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
361,111
+16.94%
|
$6,499,998
$18.0 P/Share
|
|
Jul 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,408,912
+50.0%
|
-
|
|
Jul 21
2020
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
361,111
+13.84%
|
$6,499,998
$18.0 P/Share
|
|
Jul 21
2020
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,887,193
+32.79%
|
-
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
722,222
+25.52%
|
$12,999,996
$18.0 P/Share
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
23,622
+50.0%
|
-
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,385,291
+50.0%
|
-
|